BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that a U.S. Government medical facility has purchased a BSD-500 Hyperthermia System (BSD-500). "BSD has received purchase orders for eight hyperthermia systems since September 1, 2010, the beginning of BSD's 2011 fiscal year," stated Harold Wolcott, BSD's President. "Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors. We are excited that this technology will be more widely available to patients throughout the world."
“BSD has received purchase orders for eight hyperthermia systems since September 1, 2010, the beginning of BSD's 2011 fiscal year”
The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors.
New study unveils why glioblastoma becomes resistant to treatment